Androgen receptor signalling in non-prostatic malignancies
Although androgen deprivation therapy is been extensively studies and used for metastatic disease, androgen receptor (AR) role in other cancer types where it is also expressed and functional is not well documented.
In this review, the researchers discuss the role of AR in non-prostatic cancer types and summarize ongoing AR-directed clinical trials.
The authors believe that targeting the AR system could benefit both sexes different androgen levels contribute to sexual dimorphism in cancer.
Researchers would like to see more research on cellular and molecular mechanisms of action of AR in cancer cells and the tumor microenvironment.
It would also be necessary to identify patients with non-prostatic cancer who might benefit from AR targeting therapy.
